Astrocytic centrin-2 expression in entorhinal cortex correlates with Alzheimer's disease severity

Area of Science:

• Neuroscience
• Cell Biology
• Biochemistry

Background:

• Astrogliosis, a reactive change in astrocytes, is a hallmark of neurological diseases, including Alzheimer's disease (AD).
• In AD, reactive astrocytes surround amyloid plaques and exhibit altered protein expression and calcium signaling, contributing to neuroinflammation.
• Understanding astrocyte calcium signaling is crucial for elucidating AD pathogenesis.

Purpose of the Study:

• To investigate the role of centrin-2 (CETN2), a newly identified astrocyte marker, in the context of Alzheimer's disease.
• To determine if astrocytic CETN2 expression is altered in AD and correlates with disease progression.

Main Methods:

• Immunoblotting, immunohistochemistry, and targeted mass spectrometry were employed.
• CETN2 expression patterns were analyzed in human brain samples from control and sporadic AD patients.
• Colocalization studies with reactive glia markers (STAT3, NFATc3, YKL-40) were performed.

Main Results:

• A positive correlation was observed between entorhinal CETN2 immunoreactivity and neurocognitive impairment in AD patients.
• CETN2 expression linearly correlated with the abundance of amyloid depositions and neurofibrillary tangles, indicating a link to AD progression.
• CETN2-positive astrocytes exhibited a clustered pattern and colocalized with markers of reactive glia, suggesting a role in AD-induced astrogliosis.

Conclusions:

• Centrin-2 (CETN2) is identified as a novel component of the astrocytic calcium signaling toolkit that is altered in Alzheimer's disease.
• CETN2 expression is associated with AD progression and neuroinflammation, highlighting its potential role in disease pathogenesis.
• These findings suggest CETN2 as a potential biomarker and therapeutic target in Alzheimer's disease research.